Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017
July 27 2017 - 4:30PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that the Company
will host a conference call and live audio webcast on Thursday,
August 3, 2017, at 4:30 p.m. ET to report second quarter 2017
financial results and provide a corporate update.
To participate in the conference call, please
dial 855-445-2816 (domestic) or 484-756-4300 (international) and
refer to conference ID 57769313. A live webcast of the call can be
accessed under “Events and Presentations” in the News &
Investors section of the Company’s website at
www.CaraTherapeutics.com.
An archived webcast recording will be available
on the Cara website beginning approximately two hours after
the call.
About Cara
Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates, led
by CR845, that target the body's peripheral nervous system and have
demonstrated initial efficacy in patients with moderate-to-severe
pruritus and pain without inducing many of the undesirable side
effects typically associated with currently available pain
therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024